US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1
Patent 11952421 was granted and assigned to Bristol-Myers Squibb Company on April, 2024 by the United States Patent and Trademark Office.
Name
# Contributions
Last Contribution
Find more entities like US Patent 11952421 Bispecific antibodies against CD3EPSILON and ROR1
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
